Novonesis: The enzyme champion that no one can copy

5-year stock timeline

Key Points

From recommendation (January 4, 2026)

• Market leader with almost 50% share in the specialty enzyme segment - decades of research and thousands of patented enzymes create an almost uncopyable competitive advantage
• Merger with Chr. Hansen successfully completed, sales growth forecast for 2025 raised to 7-8% organically
• Enzymes de facto indispensable in food, detergents and biofuels - chemical alternatives more expensive, more harmful to the environment and problematic from a regulatory perspective
• P/E ratio 15.5 with structural growth due to decarbonization pressure and expansion in emerging markets
• New Quara LowP product line addresses growing market for sustainable aviation fuel

Investment Thesis

From recommendation (January 4, 2026)

Novonesis unites according to the Chr. Hansen merger offers a unique combination of technological dominance, operational scaling and structural tailwind. The company controls a market in which enzymes are not only efficient, but increasingly without alternative - be it in food processing, biofuels or low-temperature detergents. Entering this market requires decades of research, extensive master collections, regulatory approvals and deep customer relationships - hurdles that remain virtually insurmountable. At the same time, global decarbonization pressure is structurally driving demand for biological process solutions, while the merger is showing initial synergies and strategically expanding the portfolio. With a P/E ratio of 15.5, an increased growth forecast and expansion potential in emerging markets, the share offers solid fundamental data with limited disruption risk until at least 2035.

Key risks and downside factors

Novozymes A/S merged with Chr. Hansen on January 29, 2024, and now operates as Novonesis (NSIS-B / ISIN DK0060336014). The company holds a global position in industrial enzymes, microbial solutions, and food and animal nutrition ingredients. Its competitive field spans large diversified chemical and ingredient multinationals—DuPont, dsm-firmenich, and BASF among them—alongside specialized enzyme and biotech firms like AB Enzymes and Lesaffre, plus newer synthetic-biology players including Codexis and Ginkgo. The company faces structural pressures: margin compression from competition, the ongoing costs and complexities of integrating the merger, vulnerability to rapid shifts in technology and intellectual property, and the cyclical nature of commodity inputs and end-market demand.

• Intense competition from large diversified chemical and ingredient players alongside specialist enzyme and biotech firms creates sustained pricing pressure, with real risk of margin compression [Mordor Intelligence; Novonesis].
• Regulatory, antitrust, and divestiture risk can materially affect merger outcomes. Required divestitures shrink the combined entity's scale, while ongoing compliance and integration costs erode profitability gains [Novonesis announcement; Nasdaq filings].
• Rapid advances in directed evolution and synthetic-biology platforms pose a technology and IP risk. Companies like Codexis and Ginkgo are shortening product lifecycles, which could force elevated R&D spending on incumbents simply to maintain competitive position [Codexis; Ginkgo].
• Supply-chain, commodity and end-market cyclicality create material headwinds—energy and raw-material costs swing sharply, manufacturing disruptions ripple through operations, and demand in detergents, feeds and food moves in predictable cycles. Together, these amplify both revenue and margin volatility in ways that can surprise if you're not watching the underlying drivers [Novonesis presentation; industry reports].

Competitive landscape

Novozymes, now operating as part of the merged entity Novonesis (NSIS-B on Nasdaq Copenhagen), leads the global biosolutions and industrial-enzymes market across food, agriculture, household care, and industrial biotechnology. The competitive landscape is fragmented: large specialty-ingredient and chemical groups like IFF and DSM-Firmenich bundle enzymes and cultures into broader portfolios, while specialist firms such as Codexis focus on protein engineering and biocatalysis. Regional low-cost producers add further pressure on margins and market share. The near-term risk profile centers on post-merger integration execution, R&D and intellectual-property protection, and regulatory exposure—each capable of materially affecting operations and financial results.

Catalysts

From recommendation (January 4, 2026)

• Further synergy effects from Chr. Hansen merger could noticeably improve margins from 2026
• Regulatory tightening for decarbonization structurally driving demand for enzyme-based solutions
• Breakthroughs in sustainable aviation fuels with Quara LowP could open up new growth segment
• Successful expansion in emerging markets with rising demand for food and detergent enzymes

Analysis

From recommendation (January 4, 2026)

Performance Figures of Novonesis (Novozymes) A/S

in DKK

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

Frequently Asked Questions

From recommendation (January 4, 2026)

Key Metrics

From recommendation (January 4, 2026)

Valuation Metrics

Profitability Metrics

Growth Metrics

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.